BioCentury
ARTICLE | Company News

Kite, Daiichi Sankyo deal

January 13, 2017 7:56 PM UTC

Kite granted Daiichi Sankyo rights in Japan to develop and commercialize chimeric antigen receptor (CAR) T cell therapy axicabtagene ciloleucel (KTE-C19). Kite will receive $50 million up front and is eligible for up to $200 million in milestones, plus low- to mid-double-digit royalties. Daiichi is responsible for development and commercialization in Japan. Daiichi also may opt to license additional Kite candidates, including KITE-718, for up to $200 million each in combined upfront and milestones, plus low- to mid-double-digit royalties...